$ARX

Accelerant To Be Acquired By Thoma Bravo

Accelerant Holdings (ARX) agreed to be acquired by Thoma Bravo in an all-cash deal valued at over $4 billion. Accelerant shareholders will receive $20.25 per share, a 49% premium to Aug. 12’s close. The deal is expected to close in 1H 2027 and take the firm private. ARX shares rose premarket.

Original reporting
Published Aug 13, 2026, 1:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 1:59 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Accelerant To Be Acquired By Thoma Bravo — source image
Decision brief

The 30-second read

$ARXBullishHigh
01

Why it matters

The disclosed $20.25/share all-cash consideration and expected privatization/delisting materially reprice ARX and shift trading toward takeover-arbitrage behavior until closing in H1 2027.

02

Market read

A large, all-cash take-private deal with a stated premium and delisting timeline is a direct, tradable catalyst for ARX and deal-spread positioning.

03

What to watch

Voting-right concentration (Altamont-linked holders controlling ~82%) can reduce shareholder-approval risk, but regulatory review and deal timing still drive spread compression or widening.

Relevance 9/10Novelty 9/10Timing: deal terms disclosed pre-market today; close expected in H1 2027

Background

Accelerant Holdings (ARX) is an insurance company agreeing to an all-cash acquisition by Thoma Bravo, with shareholders receiving a fixed per-share price.

Company-level read

Ticker impact

$ARXBullishHigh confidence
Context

Accelerant Holdings agreed to be acquired by Thoma Bravo in an all-cash deal worth more than $4B, taking it private.

Expected impact

Shares likely trade near the $20.25 offer price with volatility around deal process milestones and regulatory/financing risk.

Evidence & confidence

The article discloses the all-cash price ($20.25/share), premium vs Aug 12 close, and expected privatization/delisting timeline (H1 2027), which are direct drivers of valuation and spread behavior.

Market effects

Private-equity-backed consolidation signal for the insurance sector, potentially supporting M&A appetite and deal-spread liquidity.

Primarily US-listed takeover dynamics; limited direct regional spillover beyond US insurance M&A sentiment.

Moderate global relevance via cross-border PE capital allocation, but the transaction is US-focused and company-specific.

Counterpoint

The stock may not hold the offer premium if deal conditions, financing, or regulatory hurdles emerge before closing.

Key entities

  • Accelerant Holdings

    Subject of the acquisition agreement; shareholders to receive $20.25 per share in cash.

  • Thoma Bravo

    Private equity firm acquiring Accelerant in an all-cash transaction worth more than $4B.

  • Altamont Capital Partners

    Largest investor; Altamont-linked entities control about 82% of voting rights and agreed to support the deal.

Related articles

$ARXHighAI 9/10

Accelerant Shares Surge 43% On Thoma Bravo Buyout Deal

Accelerant Holdings (ARX) shares rose about 43% after the company said it has a definitive agreement to be acquired by Thoma Bravo in an all-cash deal worth more than $4 billion. ARX was trading around $19.52, up $5.91, after opening near $19.61 versus a prior close of $13.61.

$ARXMedAI 8/10

Accelerant Holdings (ARX): Results of Operations and Financial Condition

Accelerant Holdings (ARX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 d286225dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Accelerant Announces Second Quarter 2026 Results Accelerant Cancels Earnings Conference Call Following Announcement of Agreement with Thoma Bravo to Become a Private Company Second Quarter 2026 Results • Exchange Written Pr

$ARXMed

ARX: Q2 2026 delivered robust operational and financial results, with the Shell acquisition progressing

Less than 1 min read Q2 2026 saw strong production growth and higher realized prices, driving a 20% year-over-year increase in funds from operations and a 94% rise in free funds flow per share. Net income declined 9% per share due to lower risk management gains and higher costs. The pending $22 billion Shell acquisition remains on track. Original document: ARC Resources Ltd. [ARX] Interim report — Jul. 30 2026 Disclaimer This is an AI-generated summary and may contain inaccuracies.

$ARXMed

ARX: Q2 2026 delivered robust production and cash flow as the $22B Shell acquisition advances

Less than 1 min read Q2 2026 saw 9% year-over-year production growth and strong cash flow, with $816 million in funds from operations and $349 million in free funds flow. The $22 billion Shell acquisition is progressing, with closing expected in Q3 2026. Original document: ARC Resources Ltd. [ARX] Earnings Release — Jul. 30 2026 Disclaimer This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.